Phase 3 efficacy supports approval prospects, but cash burn and long-dated first-line data remain material considerations [13][47][32].
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2026-05-15 |
| Length | 47 minutes |
| EPS | $-0.97 |
| EPS consensus | $-1.07 |
| Revenue | $3.8M |
| Revenue consensus | $2.9M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q4 FY25 · Q2 FY25
All CELC earnings · Back to CELC overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.